NO20066055L - Pyridinderivater - Google Patents
PyridinderivaterInfo
- Publication number
- NO20066055L NO20066055L NO20066055A NO20066055A NO20066055L NO 20066055 L NO20066055 L NO 20066055L NO 20066055 A NO20066055 A NO 20066055A NO 20066055 A NO20066055 A NO 20066055A NO 20066055 L NO20066055 L NO 20066055L
- Authority
- NO
- Norway
- Prior art keywords
- pyridine derivatives
- preparation
- relates
- solvates
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Foreliggende oppfinnelse vedrører forbindelser med formel (I) og farmasøytisk akseptable salter og solvater derav, fremgangsmåter til framstilling av pyridin-derivatene, samt mellomprodukter som anvendes til framstillingen av pyridinderi-vatene. Oppfinnelsen vedrører også preparater som inneholder pyridinderivater samt anvendelser av slike.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0416524A GB0416524D0 (en) | 2004-07-23 | 2004-07-23 | Pyridine derivatives |
US64607705P | 2005-01-21 | 2005-01-21 | |
PCT/IB2005/002214 WO2006011050A2 (en) | 2004-07-23 | 2005-07-12 | Pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20066055L true NO20066055L (no) | 2007-01-24 |
Family
ID=35786566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20066055A NO20066055L (no) | 2004-07-23 | 2006-12-29 | Pyridinderivater |
Country Status (17)
Country | Link |
---|---|
US (1) | US7649004B2 (no) |
EP (1) | EP1802580A2 (no) |
JP (1) | JP4056081B1 (no) |
KR (1) | KR20070026845A (no) |
AP (1) | AP2007003887A0 (no) |
AU (1) | AU2005266090A1 (no) |
BR (1) | BRPI0513717A (no) |
CA (1) | CA2574600C (no) |
CR (1) | CR8859A (no) |
EA (1) | EA200700099A1 (no) |
EC (1) | ECSP077185A (no) |
IL (1) | IL180430A0 (no) |
MA (1) | MA28747B1 (no) |
MX (1) | MX2007000885A (no) |
NO (1) | NO20066055L (no) |
TN (1) | TNSN07022A1 (no) |
WO (1) | WO2006011050A2 (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
CA2633329A1 (en) * | 2006-01-23 | 2007-07-26 | Pfizer Limited | Pyridine derivatives as sodium channel modulators |
US20100227872A1 (en) * | 2007-05-03 | 2010-09-09 | Mark Ian Kemp | Pyrazine derivatives |
BRPI0810202A2 (pt) | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
US8809380B2 (en) * | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
US9394293B2 (en) | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
TWI631105B (zh) | 2013-01-31 | 2018-08-01 | 維泰克斯製藥公司 | 作爲鈉通道調節劑之喹啉及喹噁啉醯胺 |
CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
JP6449845B2 (ja) | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
UA119147C2 (uk) | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
AU2014318979B2 (en) * | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
DK3080134T3 (en) | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
WO2016170009A1 (en) * | 2015-04-21 | 2016-10-27 | Almirall, S.A. | Amino-substituted heterocyclic derivatives as sodium channel inhibitors |
CA3063901A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
JOP20200001A1 (ar) | 2017-07-11 | 2022-10-30 | Vertex Pharma | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم |
CN111918650A (zh) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | 治疗疼痛的方法 |
WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
US20220110923A1 (en) | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
EP4347583A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4347031A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
IL308954A (en) | 2021-06-04 | 2024-01-01 | Vertex Pharma | Solid dosage forms and dosage regimens containing (2R, 3S, 4S, 5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2 -carbonyl]amino]pyridine-2-carboxamide |
AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
WO2022256679A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3332687A1 (de) | 1983-09-10 | 1985-03-28 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 2-amino-alkylpyridinen |
JPS63179869A (ja) | 1987-01-20 | 1988-07-23 | Dainippon Pharmaceut Co Ltd | ピペリジン誘導体 |
DE3933802A1 (de) | 1989-10-10 | 1991-04-18 | Basf Ag | Pyridinderivate und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
WO1991019697A1 (en) | 1990-06-19 | 1991-12-26 | Meiji Seika Kabushiki Kaisha | Pyridine derivative with angiotensin ii antagonism |
AU4515896A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
JPH09132529A (ja) | 1995-11-09 | 1997-05-20 | Ono Pharmaceut Co Ltd | 一酸化窒素合成酵素阻害剤 |
JP2000507590A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
AU706314B2 (en) | 1996-04-03 | 1999-06-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DE19831246A1 (de) | 1998-07-11 | 2000-01-13 | Clariant Gmbh | Verfahren zur Herstellung von Arylpyridinen |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
-
2005
- 2005-07-12 JP JP2007522066A patent/JP4056081B1/ja not_active Expired - Fee Related
- 2005-07-12 AU AU2005266090A patent/AU2005266090A1/en not_active Abandoned
- 2005-07-12 US US11/572,533 patent/US7649004B2/en not_active Expired - Fee Related
- 2005-07-12 BR BRPI0513717-9A patent/BRPI0513717A/pt not_active IP Right Cessation
- 2005-07-12 WO PCT/IB2005/002214 patent/WO2006011050A2/en active Application Filing
- 2005-07-12 EP EP05763394A patent/EP1802580A2/en not_active Withdrawn
- 2005-07-12 AP AP2007003887A patent/AP2007003887A0/xx unknown
- 2005-07-12 KR KR1020077001611A patent/KR20070026845A/ko not_active Application Discontinuation
- 2005-07-12 EA EA200700099A patent/EA200700099A1/ru unknown
- 2005-07-12 MX MX2007000885A patent/MX2007000885A/es unknown
- 2005-07-12 CA CA2574600A patent/CA2574600C/en not_active Expired - Fee Related
-
2006
- 2006-12-28 IL IL180430A patent/IL180430A0/en unknown
- 2006-12-29 NO NO20066055A patent/NO20066055L/no not_active Application Discontinuation
-
2007
- 2007-01-15 CR CR8859A patent/CR8859A/es not_active Application Discontinuation
- 2007-01-19 EC EC2007007185A patent/ECSP077185A/es unknown
- 2007-01-22 TN TNP2007000022A patent/TNSN07022A1/fr unknown
- 2007-01-23 MA MA29626A patent/MA28747B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP077185A (es) | 2007-02-28 |
KR20070026845A (ko) | 2007-03-08 |
JP4056081B1 (ja) | 2008-03-05 |
WO2006011050A3 (en) | 2006-10-05 |
AP2007003887A0 (en) | 2007-02-28 |
CA2574600A1 (en) | 2006-02-02 |
US7649004B2 (en) | 2010-01-19 |
WO2006011050A2 (en) | 2006-02-02 |
MA28747B1 (fr) | 2007-07-02 |
EA200700099A1 (ru) | 2007-08-31 |
IL180430A0 (en) | 2007-06-03 |
CR8859A (es) | 2007-03-02 |
CA2574600C (en) | 2010-08-31 |
MX2007000885A (es) | 2007-03-12 |
US20080312235A1 (en) | 2008-12-18 |
BRPI0513717A (pt) | 2008-05-13 |
EP1802580A2 (en) | 2007-07-04 |
TNSN07022A1 (fr) | 2008-06-02 |
AU2005266090A1 (en) | 2006-02-02 |
JP2008507503A (ja) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20066055L (no) | Pyridinderivater | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
NO20090628L (no) | Pyridizinon derivativater | |
NO20082496L (no) | Pyrazinderivater | |
NO20050828L (no) | lndol-3-svovelderivater | |
NO20071593L (no) | Pyrimidinderivater | |
NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
WO2004100865A3 (en) | New benzimidazole derivatives | |
NO20054787L (no) | Indenderivater som farmasotiske midler | |
NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
NO20060314L (no) | Nicotinamid-derivater anvendbare som PDE4-inhibitorer | |
NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
DK1517890T3 (da) | Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
NO20061045L (no) | Imidazolderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |